Eagle Pharmaceuticals, Inc.
EGRX · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -2.5% | 9.2% | -7.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 73.9% | 73.9% | 67.3% | 64.1% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 25.3% | 26.1% | 34.9% | 3.3% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 8% | 8.7% | 13.5% | -5.3% |
| EPS Diluted | 0.39 | 0.44 | 0.62 | -0.27 |
| % Growth | -11.4% | -29% | 329.6% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |